Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A pill designed to further lower ...

Merck (MRK) on Tuesday announced an agreement under which funds managed by Blackstone (BX) Life Sciences will provide the New Jersey-based pharma giant with $700M to advance a cancer therapy called ...

Merck on Monday announced the groundbreaking of its new Virginia pharmaceutical manufacturing facility, a cornerstone of the company’s $70 billion U.S. investment strategy. The 400,000-square-foot ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BERLIN — At a prime-time session on Saturday at a major cancer conference ...

Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...

Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. The move comes amid plans by President Trump to impose tariffs on ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.